ReviewAntimicrobial agents and chemotherapy2009
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.
Review in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05411744 (One-month Latent Tuberculosis Treatment for Renal Transplant Candidates), which is not on this map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Who cites it
78 citing papers in PubMed.
- Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.Clinical pharmacology in drug development · 2021Trial
- Design, Synthesis, Antimycobacterial Evaluation, and In Silico Investigation of Benzisothiazole-Based Hydrazide Derivatives as Potential Anti-Tuberculosis Agents.Chemical biology & drug design · 2026Article
- Machine learning-guided discovery of spirocyclic inhibitors targeting Mycobacterium tuberculosis FtsZ.Folia microbiologica · 2026Article
- Combined computational and classical medicinal chemistry procedure to disclose novel pyrrole-based compounds as potential antituberculosis agents.Journal of computer-aided molecular design · 2026Article
- Antimycobacterial peptides as natural therapeutics for tuberculosis: mechanisms and structural features.Frontiers in antibiotics · 2026Review
- Synthesis, DFT study, in silico ADMET evaluation, molecular docking, and QSAR analysis of new anti-tuberculosis drugs derived from 2-hydroxybenzohydrazide derivatives.Molecular diversity · 2025Article
- Risk factors for tuberculosis treatment outcomes: a statistical learning-based exploration using the SINAN database with incomplete observations.BMC medical informatics and decision making · 2025Article
- Unveiling the potential of antimicrobial peptides to combat Mycobacterium tuberculosis.Archives of microbiology · 2025Review
- From Repurposing to Refinement: Optimizing Levofloxacin for Treatment of Multidrug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2025Article
- Exploration of pyrazole-based pyridine-4-carbohydrazide derivatives as drug-resistantFuture medicinal chemistry · 2025Article
- A Mysterious Case of Primary Oral Tuberculosis in a 14-Year-Old Indian Female: A Diagnostic Enigma in a Case Report.Cureus · 2025Article
- Spirocyclic compounds: potential drug leads in the fight againstFuture medicinal chemistry · 2025Review
- Advancing the fight against tuberculosis: integrating innovation and public health in diagnosis, treatment, vaccine development, and implementation science.Frontiers in medicine · 2025Review
- Exploiting induced pluripotent stem cell-derived retinal pigment epithelium to unravel host-pathogen interaction in ocular tuberculosis: a reverse translationalFrontiers in ophthalmology · 2025Article
- Comparative study on the bioavailability and bioequivalence of rifapentine capsules in humans.Frontiers in pharmacology · 2024Article
- Antimicrobial Peptides as Immunomodulators and Antimycobacterial Agents to Combat Mycobacterium tuberculosis: a Critical Review.Probiotics and antimicrobial proteins · 2023Review
- OvercomingACS omega · 2023Review
- Polyfluorinated salicylic acid analogs do not interfere with siderophore biosynthesis.Tuberculosis (Edinburgh, Scotland) · 2023Article
- Protective Effects of Rifampicin and Its Analog Rifampicin Quinone in a Mouse Model of Obesity-Induced Type 2 Diabetes.ACS pharmacology & translational science · 2023Article
- Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers.Frontiers in immunology · 2023Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.